How Power Corrupts in Macbeth Essay -- Macbeth, power, Shakespeare,

â€Å"Power tends to corrupt and absolute power corrupts absolutely.† (John Dalberg-Acton, 1st Baron Acton) It is in human nature that the more power one desires the more corrupt actions one must do to attain it. In Shakespeare’s tragedy of Macbeth, a Scottish noble's craving for power leads him to do terrible deeds that leads to his demise. Shakespeare shows that power corrupts by using Macbeth who corrupts under the thought of have power over others. Macbeth becomes corrupt under the thought of becoming king and gaining almost complete control over the people that he rules. Macbeth wants the power badly enough to do horrible deeds such as commit regicide. Lady Macbeth becomes very ambitious and allows herself to become seduced to the idea of becoming Queen. Her ruthlessness urges Macbeth to commit regicide by questioning his love for her and his own manhood. Jane Brendon, a female critic on Macbeth comments on the Lady Macbeth’s association with Macbeth, the hero, to commit crimes which tend to show that the corruption of Macbeth is previously designed and the result that they got was foretold: Lady Macbeth certainly had the upper hand over her weak husband; she found it easy to manipulate him into murder and then getting him to think it was his own idea! She even insults him by telling him that the only way he’ll be able to prove his manhood to her is to commit murder, since he hasn’t already proved it to her by â€Å"giving her a son.† That was a very, very harsh insult because in those times, males were everything. (p.9, The Follies of Power) The essence of Macbeth lies not only in the fact that it is written by the universal talent William Shakespeare; the royal-conspiracy, the political unethical activity, the killin... ...U of Pennsylvania Press, 1994) Domhoff, G. W. (1990). The power elite and the state: How policy Is made in America. Hawthorne, NY: Aldine de Gruyter. http://www.ehow.com/about_6635615_meaning-graft-corruption https://answers.yahoo.com/question John Wain, The Living World of Shakespeare: A Playgoer’s Guide (London: Macmillan, 1965), 23. Leonard Tennenhouse, Power on Display: The Politics of Shakespeare’s Genres (New York: Methuen, 1986 Mann, M. (1977). States ancient and modern. Archives of European Sociology, 18, 226-298. Mann, M. (1993). The sources of social power: The rise of classes and nation-states, 1760-1914 (Vol. 2). New York: Cambridge University Press. Merriam-Webster, Incorporated William Shakespeare, Macbeth, in The Complete Works of William Shakespeare (Ware, Hertfordshire, England: Wordsworth Editions, Ltd., 1996), I.v.25-28.

Clinical Trial and Nucleon Assignment Notes

Nucleon Assignment Notes Porter’s 5 Forces Industry Analysis †¢Competition: Intense †¢Buyer Power: Moderate to High oBig pharma companies likely have a lot of power, although as a small firm, your power increases once you clear phases of drug trials. †¢Supplier Power: Unsure, Moderate? oThe case makes it sound like there’s not many manufacturers out there for contracting purposes. Not sure what power suppliers of raw materials have. †¢Threat of Substitutes: Moderate to High oLots of firms racing to create the next blockbuster drug or treatment for big money illnesses.However, most drugs fail, so the likelihood of a substitute is probably only moderate. †¢Threat of New Entrants: Moderate oRelatively easy to start a new small drug research firm. Just need some smart scientists. Funding is currently difficult to come by, however. Nucleon †¢Competition: Moderate to Low oThe case mentioned they were in a pretty niche area of biotech. †¢Buye r Power: Moderate to High oBig pharma companies likely have a lot of power. But if Nucleon clears phase II their power increases substantially. †¢Supplier Power: Unsure, Moderate? The case makes it sound like there’s not many manufacturers out there for contracting purposes. Not sure what power suppliers of raw materials have. †¢Threat of Substitutes: Moderate to Low oI don’t think there’s much out there in the way of burn treatments (need to check on that). †¢Threat of New Entrants: Moderate to Low oThe drug research process is slow, so any new entrant in this specific area is going to be significantly behind with little to no way to catch up. Resource Based View VRIO Value:There’s definitely value in a successful drug for burn treatment; it also presents itself as a possible cure for other ailments as well (i. . kidney failure) Rarity:Not many alternatives for burn victim treatment (assumption based on the case’s voice); large mole cule research is still new and rare, tough to get into. Imitability: Not very imitable, especially if Nucleon can gain strong patent protection. Also, the slow development time means that even if another firm could mimic a similar drug, it would take time. Organization:Nucleon is currently not organized to begin trials and manufacturing of this drug. They also don’t have a significant amount of financial backing at this point.Transaction Based Economics Hold-ups †¢Contract manufacturer could hold up Nucleon for more money if drug passes phases and becomes more likely to be successful. †¢Contract manufacturer could increase manufacturing costs, slow production, or create problems in quality in order to hold up Nucleon. Options Going Forward Option 1: Build Pilot Plant Pros †¢Nucleon keeps tighter control of IP †¢Can retain ownership of product rights through phase I and II †¢More flexibility †¢Can begin to develop staff for in-house manufacturing, making scaling later easier Cons Expensive (likely need more financial backing/don’t have enough as is) †¢Risky oDrug could fail in clinical trials (which statistically is likely) oProcess uncertainty; bacterial vs. mammalian cells †¢Distracts Nucleon’s financial and human capital away from their core, the drug R&D Option 2: Contract Manufacturing Pros †¢No major upfront capital investment †¢Access to experienced manufacturing facilities and staff immediately †¢Retain ownership of product rights through phase I and II Cons †¢Still not cheap; doesn’t save Nucleon much money over Option 1 †¢Risk of IP issues Contract specifics are very difficult to hash out due to the nature of biotech †¢No faster than building their own plant due to slow process of negotiating, knowledge transfer, then scale-up Option 3: Licensing Pros †¢No capital investment †¢Little to no risk †¢Simple; allows Nucleon to focus on the R&D à ¢â‚¬ ¢Immediate cash flow †¢Keep rights for CRP-1 for other uses (other than for burn treatment) Cons †¢Much less share in the profits if drug is successful (mortgage the company’s success) †¢Would likely lower employee morale, which could in turn decrease likelihood of success of drug †¢Risk of IP issues Clinical Trial and Nucleon Assignment Notes Nucleon Assignment Notes Porter’s 5 Forces Industry Analysis †¢Competition: Intense †¢Buyer Power: Moderate to High oBig pharma companies likely have a lot of power, although as a small firm, your power increases once you clear phases of drug trials. †¢Supplier Power: Unsure, Moderate? oThe case makes it sound like there’s not many manufacturers out there for contracting purposes. Not sure what power suppliers of raw materials have. †¢Threat of Substitutes: Moderate to High oLots of firms racing to create the next blockbuster drug or treatment for big money illnesses.However, most drugs fail, so the likelihood of a substitute is probably only moderate. †¢Threat of New Entrants: Moderate oRelatively easy to start a new small drug research firm. Just need some smart scientists. Funding is currently difficult to come by, however. Nucleon †¢Competition: Moderate to Low oThe case mentioned they were in a pretty niche area of biotech. †¢Buye r Power: Moderate to High oBig pharma companies likely have a lot of power. But if Nucleon clears phase II their power increases substantially. †¢Supplier Power: Unsure, Moderate? The case makes it sound like there’s not many manufacturers out there for contracting purposes. Not sure what power suppliers of raw materials have. †¢Threat of Substitutes: Moderate to Low oI don’t think there’s much out there in the way of burn treatments (need to check on that). †¢Threat of New Entrants: Moderate to Low oThe drug research process is slow, so any new entrant in this specific area is going to be significantly behind with little to no way to catch up. Resource Based View VRIO Value:There’s definitely value in a successful drug for burn treatment; it also presents itself as a possible cure for other ailments as well (i. . kidney failure) Rarity:Not many alternatives for burn victim treatment (assumption based on the case’s voice); large mole cule research is still new and rare, tough to get into. Imitability: Not very imitable, especially if Nucleon can gain strong patent protection. Also, the slow development time means that even if another firm could mimic a similar drug, it would take time. Organization:Nucleon is currently not organized to begin trials and manufacturing of this drug. They also don’t have a significant amount of financial backing at this point.Transaction Based Economics Hold-ups †¢Contract manufacturer could hold up Nucleon for more money if drug passes phases and becomes more likely to be successful. †¢Contract manufacturer could increase manufacturing costs, slow production, or create problems in quality in order to hold up Nucleon. Options Going Forward Option 1: Build Pilot Plant Pros †¢Nucleon keeps tighter control of IP †¢Can retain ownership of product rights through phase I and II †¢More flexibility †¢Can begin to develop staff for in-house manufacturing, making scaling later easier Cons Expensive (likely need more financial backing/don’t have enough as is) †¢Risky oDrug could fail in clinical trials (which statistically is likely) oProcess uncertainty; bacterial vs. mammalian cells †¢Distracts Nucleon’s financial and human capital away from their core, the drug R&D Option 2: Contract Manufacturing Pros †¢No major upfront capital investment †¢Access to experienced manufacturing facilities and staff immediately †¢Retain ownership of product rights through phase I and II Cons †¢Still not cheap; doesn’t save Nucleon much money over Option 1 †¢Risk of IP issues Contract specifics are very difficult to hash out due to the nature of biotech †¢No faster than building their own plant due to slow process of negotiating, knowledge transfer, then scale-up Option 3: Licensing Pros †¢No capital investment †¢Little to no risk †¢Simple; allows Nucleon to focus on the R&D à ¢â‚¬ ¢Immediate cash flow †¢Keep rights for CRP-1 for other uses (other than for burn treatment) Cons †¢Much less share in the profits if drug is successful (mortgage the company’s success) †¢Would likely lower employee morale, which could in turn decrease likelihood of success of drug †¢Risk of IP issues

Making A Job Application For Business Law - 1467 Words

Before considering filling a job application I do a deep research the company before submitting any personal information. Since there are many shell or Ghost Companies and Companies that commit fraud. In the class on what little I ve had the opportunity to be present but I ve always been able to read the chapters of the class assigned to us the students, learned to identify several areas of law especially that are relevant to business and the Importance of the rule to those areas of law, how the rule of law limits government, how the rule of law Protects people from harmful business practices and why the rule of law is important to business. In my opinion one thing that I can say that if you do not have the knowledge to identify these†¦show more content†¦Is something that call their attention and always works. Normally before filling a job application I make a list of my skill, which are the most notable, if I use my past work and looking assessments which are the best qua lified and which ones I need to improve. I always analyzed myself as a person, I also use personal assessments like asking to friends and family as they observe and categorize my community work. These are aspects that are worth gold when making a resume and fill out your application for a Job. I have always considered that the more experience in my future profession or future as I would describe it is always good to keep in mind that experiences make you be better spent to best boss in the not too near future. Your goals are more serious and easier as you get on the field knowledge. For example this one on my favorite Cover letter: Dear Juan Done: I am writing in response to your advertisement in 113 east 13 street for a Finance Consultant position. After reading your job description, I am confident that my skills and my passion for Helps clients accomplish financial objectives are a perfect match for this position. I would bring to your company a broad range of skills, including: †¢ Business Knowledge, †¢ Communications Skills (listening, verbal, written), †¢ Analytical/Research Skills †¢ Computer/Technical Literacy †¢